摘要
目的:评价紫杉醇脂质体(LEP)治疗非小细胞肺癌(NSCLC)的疗效和安全性。方法:检索Medline、Embase、PubMed、万方和中国期刊全文数据库(检索时间均为1980年至2011年7月31日)以及Cochrane图书馆系统评价和临床对照试验数据库(2011年第2期),收集以紫杉醇(PTX)为对照的LET治疗NSCLC的随机对照试验。根据纳入标准对文献进行筛选和评估,并进行meta分析,比较LEP与PTX治疗NSCLC的有效率和不良反应发生率,结果以相对危险系数(RR)、比值比(OR)及其95%可信区间(CI)表示。结果:共检索到相关文献1057篇,经筛选最终纳入符合标准的文献1 1篇,共有NSCLC患者627例,其中LEP组329例,PTX组298例。meta分析结果显示,治疗有效率2组之间差异无统计学意义(RR=1.16,95%CI为0.93～1.46,P=0.19);白细胞减少、血小板减少、贫血以及脱发发生率2组之间差异无统计学意义(P>0.05),而恶心呕吐、皮疹、肌肉痛、周围神经炎和呼吸困难发生率LEP组均低于PTX组,其OR(95%CI)分别为0.48(0.33～0.69)、0.17(0.08～0.40)、0.23(、0.15～0.35)、0.41(0.21～0.81)和0.18(0.06～0.50),差异均有统计学意义(均P<0.01)。结论:LEP具有与PTX相似的疗效,但较PTX有更好的安全性。
Objective：To evaluate the efficacy and safety of liposome encapsulated paclitaxel（LEP） in the treatment of patients with non-small-cell lung cancer（NSCLC）.Methods：Medline,Embase,PubMed,Wanfang,CNKI database（from 1980 to 31 July 2011）,Cochrane systematic evaluation and controlled trials register in Cochrane Library（Issue 2,2011） were searched.The randomized controlled trials（RCT） of LEP therapy compared with paclitaxel（PTX） in patients with NSCLC were collected.According to the inclusion criteria,the articles were selected,evaluated,and meta-analyzed.The treatment efficiency and the incidence of adverse reactions between LEP and PTX in patients with NSCLC were compared and their results were presented in relative risk（RR） or odds ratio（OR） with 95%confidence interval（CI）.Results：A total of 1057 related articles were searched and 11 RCT were selected according to the inclusion and exclusion criteria.A total of 627 patients were entered in this study.Of them,329 patients were in the LEP group and 298 patients were in the PTX group.The results of meta-analysis showed that the differences in the treatment efficiency between the LEP and the PTX groups were not significant（RR = 1.16,95%CI：0.93-1.46,P =0.19）;the differences in the incidence of leukopenia,thrombocytopenia,anemia,hair loss between the 2 groups were not significant（P0.05 ）.The incidence of nausea and vomiting,rash,myalgia,peripheral neuritis,and dyspnea were lower in the LEP group than in the PTX group,their OR（95%CI） were 0.48（0.33-0.69）,0.17（0.08-0.40）,0.23（0.15-0.35）,0.41（0.21-0.81）,and 0.18 （0.06-0.50）,respectively;the differences were significant（all P0.01）.Conclusion：LEP is similar to PTX in efficacy,but LEP is safer than PTX.
出处
《药物不良反应杂志》
2011年第4期205-212,共8页
Adverse Drug Reactions Journal
关键词
紫杉醇脂质体
紫杉醇
非小细胞肺癌
META分析
liposome encapsulated paclitaxel
paclitaxel
non-small-cell lung cancer
meta-analysis
